[go: up one dir, main page]

MX2022004808A - Métodos para tratar el cáncer de próstata. - Google Patents

Métodos para tratar el cáncer de próstata.

Info

Publication number
MX2022004808A
MX2022004808A MX2022004808A MX2022004808A MX2022004808A MX 2022004808 A MX2022004808 A MX 2022004808A MX 2022004808 A MX2022004808 A MX 2022004808A MX 2022004808 A MX2022004808 A MX 2022004808A MX 2022004808 A MX2022004808 A MX 2022004808A
Authority
MX
Mexico
Prior art keywords
prostate cancer
methods
treating prostate
treatment
formula
Prior art date
Application number
MX2022004808A
Other languages
English (en)
Inventor
Andrew P Crew
Jing Wang
Lawrence B Snyder
Iii Royal J Haskell
Marcia Dougan Moore
Original Assignee
Arvinas Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvinas Operations Inc filed Critical Arvinas Operations Inc
Publication of MX2022004808A publication Critical patent/MX2022004808A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente solicitud se refiere al tratamiento y/o la prevención del cáncer de próstata, que incluye cáncer de próstata metastásico y/o resistente a la castración, en un sujeto que necesita tratamiento, que comprende administrar un compuesto de la Fórmula (I), (ver fórmula I), o una sal, enantiómero, estereoisómero, solvato, polimorfo, derivado isotópico o profármaco farmacéuticamente aceptable de este, en donde R1 , R2 , R3 , X 1 , X2 , X3 , X4 , y n se definen en la presente descripción.
MX2022004808A 2019-10-22 2020-10-21 Métodos para tratar el cáncer de próstata. MX2022004808A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962924655P 2019-10-22 2019-10-22
US201962945418P 2019-12-09 2019-12-09
US202063028843P 2020-05-22 2020-05-22
US202063032453P 2020-05-29 2020-05-29
PCT/US2020/056684 WO2021081108A1 (en) 2019-10-22 2020-10-21 Methods of treating prostate cancer

Publications (1)

Publication Number Publication Date
MX2022004808A true MX2022004808A (es) 2022-06-08

Family

ID=73449188

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004808A MX2022004808A (es) 2019-10-22 2020-10-21 Métodos para tratar el cáncer de próstata.

Country Status (10)

Country Link
US (2) US20210113557A1 (es)
EP (1) EP4048236A1 (es)
JP (2) JP7716396B2 (es)
KR (1) KR20220087482A (es)
CN (1) CN115135313A (es)
AU (1) AU2020370150A1 (es)
CA (1) CA3158411A1 (es)
IL (1) IL292359A (es)
MX (1) MX2022004808A (es)
WO (1) WO2021081108A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
CA3038979A1 (en) 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
CN114133379B (zh) * 2020-09-04 2024-02-13 南京奥瑞药业有限公司 一种杂环化合物、其制备方法、中间体、组合物以及应用
WO2022087125A1 (en) 2020-10-21 2022-04-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor protein
MX2023006883A (es) * 2020-12-11 2023-06-23 Arvinas Operations Inc Metodos para tratar el cancer de prostata.
CN113620931B (zh) * 2021-09-13 2023-06-09 中国海洋大学 一种雄激素受体抑制剂及其用途
WO2023205481A1 (en) * 2022-04-21 2023-10-26 Arvinas Operations, Inc. A combination for use in treating prostate cancer comprising arv-100 and abiraterone
WO2024233696A1 (en) * 2023-05-09 2024-11-14 Arvinas Operations, Inc. Bavdegalutamide for treating prostate cancer without ar l702h mutation
WO2025122895A1 (en) 2023-12-08 2025-06-12 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US20140255413A1 (en) * 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
KR20160023641A (ko) * 2013-03-15 2016-03-03 아이슈티카 인코포레이티드 아비라테론 아세테이트 제제
IN2014MU00303A (es) * 2014-01-28 2015-09-11 Cipla Ltd
MX387318B (es) * 2014-04-14 2025-03-18 Arvinas Operations Inc Moduladores de la proteólisis basados en imida y métodos de uso asociados.
ES2751300T3 (es) * 2014-11-21 2020-03-31 Biohaven Therapeutics Ltd Formulación sublingual de riluzol
KR20230005416A (ko) * 2016-06-10 2023-01-09 유니버시티 오브 테네시 리서치 파운데이션 선택적 안드로겐 수용체 분해제(sard) 리간드 및 이의 사용 방법
JOP20190067A1 (ar) * 2016-09-30 2019-03-28 Janssen Pharmaceutica Nv طُرق تشخيص وعلاج سرطان البروستاتا النقيلي المقاوم للإخصاء والمقاوم أو الحساس لأبيراتيرون أسيتات-الهرمون القشري السكري
CA3038979A1 (en) * 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor

Also Published As

Publication number Publication date
IL292359A (en) 2022-06-01
WO2021081108A1 (en) 2021-04-29
KR20220087482A (ko) 2022-06-24
CN115135313A (zh) 2022-09-30
JP7716396B2 (ja) 2025-07-31
US20230128132A1 (en) 2023-04-27
US20210113557A1 (en) 2021-04-22
EP4048236A1 (en) 2022-08-31
CA3158411A1 (en) 2021-04-29
JP2022553954A (ja) 2022-12-27
AU2020370150A1 (en) 2022-05-12
JP2025157436A (ja) 2025-10-15

Similar Documents

Publication Publication Date Title
MX2022004808A (es) Métodos para tratar el cáncer de próstata.
CL2023001655A1 (es) Métodos para tratar el cáncer de próstata
CO2022002729A2 (es) Métodos de tratamiento del cáncer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrógenos
BR112022022988A2 (pt) Métodos de tratamento do câncer de próstata
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
SA522432955B1 (ar) Kras g12c مثبطات
AR122783A2 (es) Inhibidores de kras g12c y métodos para su uso
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
MX2022000271A (es) Inhibidores de la quinasa progenitora hematopoyetica 1 y usos de los mismos.
EA202193015A1 (ru) Ингибиторы cdk
UY37133A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
MX380798B (es) Profármacos de alvocidib que tienen una biodisponibilidad aumentada.
MX2024009926A (es) Composiciones y metodos para tratar trastornos del snc.
JOP20190191A1 (ar) وحدات شجرية علاجية
WO2020033838A3 (en) Treatment of egfr-mutant cancer
MX2017012123A (es) Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
AR126849A1 (es) Compuestos de quinazolina para tratamiento de enfermedad
MX2021006724A (es) Compuestos de halo-alilamina y uso de los mismos.
CO2022015891A2 (es) Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres
MX2021009206A (es) Terapias contra el cancer.
MX2022003845A (es) Tratamientos cognitivos medicinales.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety